Bank of America Cuts Humana (NYSE:HUM) Price Target to $260.00

Humana (NYSE:HUM - Get Free Report) had its target price dropped by Bank of America from $320.00 to $260.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a "neutral" rating on the insurance provider's stock. Bank of America's target price would indicate a potential upside of 8.82% from the company's previous close.

A number of other equities analysts have also issued reports on the stock. Guggenheim assumed coverage on shares of Humana in a research report on Wednesday, April 9th. They set a "buy" rating and a $326.00 target price on the stock. Wall Street Zen lowered Humana from a "buy" rating to a "hold" rating in a research report on Saturday. Mizuho upped their target price on shares of Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a research report on Wednesday, April 9th. JPMorgan Chase & Co. reduced their target price on shares of Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 18th. Finally, Truist Financial dropped their price target on shares of Humana from $305.00 to $280.00 and set a "hold" rating for the company in a research note on Tuesday. Seventeen equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $280.76.

Humana Stock Performance

HUM traded up $3.53 during midday trading on Tuesday, reaching $238.92. The company's stock had a trading volume of 1,797,102 shares, compared to its average volume of 1,796,676. Humana has a twelve month low of $212.45 and a twelve month high of $406.46. The stock has a market cap of $28.84 billion, a P/E ratio of 24.04, a PEG ratio of 2.05 and a beta of 0.43. The company has a fifty day simple moving average of $249.53 and a 200 day simple moving average of $261.98. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, beating analysts' consensus estimates of $10.07 by $1.51. The firm had revenue of $32.11 billion during the quarter, compared to the consensus estimate of $32 billion. Humana had a net margin of 1.02% and a return on equity of 11.70%. The business's revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the firm earned $7.23 EPS. Research analysts expect that Humana will post 16.47 earnings per share for the current year.

Hedge Funds Weigh In On Humana

Hedge funds and other institutional investors have recently made changes to their positions in the company. Dodge & Cox grew its position in shares of Humana by 106.7% in the 4th quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock valued at $2,587,345,000 after acquiring an additional 5,264,045 shares during the period. Vanguard Group Inc. grew its holdings in Humana by 15.8% during the fourth quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock worth $3,254,899,000 after purchasing an additional 1,751,857 shares during the period. Norges Bank acquired a new position in Humana during the fourth quarter worth approximately $416,202,000. AQR Capital Management LLC raised its stake in Humana by 3,257.5% in the first quarter. AQR Capital Management LLC now owns 1,162,600 shares of the insurance provider's stock valued at $307,624,000 after buying an additional 1,127,973 shares during the period. Finally, Pzena Investment Management LLC lifted its position in shares of Humana by 44.0% in the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider's stock valued at $915,736,000 after buying an additional 1,103,132 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.